Abstract

�The Effect of Pregabalin on the Prevention of Succinylcholine-Induced Fasciculation and Myalgia�, published in the June 2020 issue 2020;35(3):255-259, contains errors in matching data for Table 2 and Figure 2. In addition, the myalgia severity data were missing, and the following text should be added to the Results section: �In the placebo group, 14 patients (28%) had no myalgia, 20 patients (40%) had muscle stiffness and pain related to one region, and 13 patients (26%) had muscle stiffness and pain that is spontaneously expressed by the patient and may require an analgesic, and 2 patients (4%) had diffuse muscle pain with unbearable discomfort. Myalgia severity in the pregabalin group was lower than the placebo group, 23 patients (46%) had no myalgia, 21 patients (42%) had muscle stiffness and pain related to one region, and 6 patients (6%) had muscle stiffness and pain that is spontaneously expressed by the patient and may require an analgesic, and no patient had diffuse muscle pain with unbearable discomfort. A t test showed a significant difference in the severity of myalgia between the two groups (P = .012).� The corrected versions of Table 2 and Figure 2 appear below. The authors apologize for any inconvenience that the errors may have caused. © 2021 American Society of PeriAnesthesia Nurses